Clinical Scorecard: Case Study and Literature Analysis of Type B Insulin Resistance with Extreme Glycemic Variability
At a Glance
Category
Detail
Condition
Key Mechanisms
Target Population
Middle-aged women, but may occur in younger individuals and diverse ethnic groups, including young Hispanic women.
Care Setting
Key Highlights
TBIR is characterized by severe insulin resistance and hyperglycemia, with a biphasic glycemic response due to autoantibodies acting as partial agonists.
Early recognition and immunosuppressive therapy are crucial for remission and management of complications.
Guideline-Based Recommendations
Diagnosis
Management
Initiate high-dose insulin therapy and consider adjunctive metabolic agents, including GLP-1 receptor agonists.
Utilize immunosuppressive therapy, such as rituximab and azathioprine, for severe cases.
Monitoring & Follow-up
Risks
Patient & Prescribing Data
Combination of high-dose insulin, GLP-1 receptor agonists (e.g., semaglutide), and immunosuppressive agents can optimize treatment.
Clinical Best Practices
Early diagnosis is essential for effective management.
Individualize immunosuppressive regimens based on patient response and monitor for complications.
